+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Postpartum Depression Treatment Market by Treatment Type, Patient Severity, Age Group, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Postpartum Depression Treatment Market by Treatment Type, Patient Severity, Age Group, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Sale

Postpartum Depression Treatment Market by Treatment Type, Patient Severity, Age Group, End User, Distribution Channel - Global Forecast 2026-2032

  • Report

  • 199 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 5639504
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Postpartum Depression Treatment Market is projected to reach USD 1.15 Billion in 2026. It is expected to continue growing at a CAGR of 7.65%, reaching USD 1.80 Billion by 2032.

Postpartum depression treatment is moving from episodic, stigma-constrained care toward a systematic maternal mental health model that combines screening, psychotherapy, pharmacotherapy, care navigation, and digital follow-up. The World Health Organization recognizes perinatal mental health conditions as a major public health concern, and the U.S. CDC reports that approximately 1 in 8 women with a recent live birth experience symptoms of postpartum depression, underscoring the need for scalable and timely treatment pathways.

The treatment landscape includes evidence-based psychotherapies such as cognitive behavioral therapy and interpersonal therapy, commonly used antidepressants, and newer neuroactive steroid therapies designed specifically for postpartum depression. Demand is also being shaped by expanded maternal health policies, telebehavioral health adoption, and greater recognition that untreated postpartum depression can affect maternal functioning, infant bonding, breastfeeding, family stability, and long-term child development.

Transformative Shifts in the Treatment Landscape

The most important shift in postpartum depression treatment is the transition from general depression management to condition-specific care. The U.S. FDA approval of brexanolone in 2019 and zuranolone in 2023 validated a dedicated pharmacological pathway for postpartum depression and increased attention on faster-acting options for patients with clinically significant symptoms.

Health systems are also embedding depression screening into obstetric, pediatric, and primary care visits using validated tools such as the Edinburgh Postnatal Depression Scale and PHQ-9. This is changing treatment demand from one-time medication use toward integrated care models that include diagnosis, referral, therapy access, medication management, lactation-aware counseling, and relapse monitoring during the first year after delivery.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly relevant to postpartum depression treatment through risk stratification, symptom monitoring, patient engagement, and clinical workflow support. AI-enabled tools can help identify patients at higher risk by analyzing structured health records, screening scores, prior psychiatric history, obstetric complications, sleep patterns, and social determinants of health, provided models are validated and deployed with clinician oversight.

The cumulative opportunity is not to replace mental health professionals but to reduce delays in detection and follow-up. AI chat interfaces, remote monitoring, and natural language processing can improve outreach between appointments, but industry leaders must address bias, privacy, informed consent, maternal safety, and escalation protocols for suicidality or psychosis. Verified clinical performance, transparent model governance, and regulatory-grade evidence will be critical differentiators.

Key Regional Insights

North America remains a leading region for postpartum depression treatment adoption due to established screening recommendations, U.S. FDA-approved therapies, commercial insurance coverage, Medicaid maternal health initiatives, and high telehealth penetration. The United States has accelerated innovation through dedicated drug approvals and postpartum coverage reforms, while Canada’s universal healthcare framework supports broader access to perinatal mental health services, although specialist wait times and rural access gaps remain challenges.

Europe benefits from national health systems, clinical guidance, and growing investment in perinatal mental health teams, particularly in Western Europe. The European Union’s focus on women’s health equity, cross-border health data standards, and digital health interoperability is strengthening structured care pathways, while country-level reimbursement, workforce availability, and access to specialist perinatal psychiatry continue to influence uptake.

Asia-Pacific presents a substantial long-term access opportunity because of its birth volume, expanding healthcare infrastructure, and rising public awareness in China, India, Japan, South Korea, and Australia. Latin America is gaining momentum through maternal health programs, primary care expansion, and digital consultation models, but affordability, uneven insurance coverage, and specialist shortages limit consistent treatment access. The Middle East, led by GCC health transformation programs, is improving women’s health services and digital care delivery, while Africa faces the most significant treatment gap due to workforce shortages, stigma, limited screening, and insufficient integration of mental health into maternal care.

Key Group Insights

Within ASEAN, postpartum depression treatment demand is shaped by rapid urbanization, mobile-first healthcare behavior, and uneven mental health capacity across member states. Digital screening, nurse-led counseling, and community-based maternal care can improve access, but language localization, stigma reduction, referral capacity, and workforce training are essential for sustainable implementation.

The GCC is advancing maternal health through hospital modernization, women’s health initiatives, insurance reforms, and national digital health strategies, creating opportunities for premium clinical programs and culturally adapted telepsychiatry. The European Union is positioned for protocol-driven expansion because of strong public health governance, standardized clinical quality expectations, and women’s health policy momentum, although reimbursement, prescribing pathways, and service implementation remain country-specific.

BRICS countries represent a high-volume access opportunity because China, India, Brazil, Russia, and South Africa combine large birth populations with expanding healthcare investment and variable access to psychiatric care. G7 markets lead in regulatory sophistication, clinical research, guideline adoption, pharmacovigilance, and reimbursement experimentation. NATO countries add a distinct focus on military families, where deployment stress, relocation, social isolation, and access continuity can intensify maternal mental health needs and require coordinated postpartum depression treatment pathways.

Key Country Insights

The United States is the most commercially mature postpartum depression treatment environment, supported by CDC surveillance, ACOG screening guidance, U.S. FDA-approved therapies, telehealth adoption, and expanding postpartum Medicaid coverage in many states. Canada emphasizes publicly funded care and perinatal mental health programs, while Mexico and Brazil show growing need for scalable screening, telehealth, primary care integration, and lower-cost treatment options to address access gaps.

In Europe, the United Kingdom benefits from NICE guidance and specialist perinatal mental health services within the NHS. Germany and France have strong healthcare systems, reimbursement infrastructure, and growing attention to maternal mental health, Italy and Spain show rising awareness within maternity and primary care pathways, and Russia presents demand potential but faces regional disparities in mental health access and service availability.

Across Asia-Pacific, China and India represent major volume opportunities due to large birth cohorts, improving maternal health systems, and expanding digital healthcare use. Japan, South Korea, and Australia have more developed clinical infrastructure, with Australia standing out for strong public discussion of perinatal mental health and widely available digital support resources. These markets will reward organizations that combine evidence-based treatment, culturally appropriate engagement, lactation-aware counseling, and postpartum follow-up continuity.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize integrated care models that connect obstetrics, pediatrics, psychiatry, primary care, pharmacy services, and digital follow-up. Winning strategies will focus on earlier screening, faster referral, evidence-based psychotherapy access, medication safety counseling, lactation-sensitive treatment decisions, and clear escalation pathways for severe depression, suicidality, or postpartum psychosis.

Pharmaceutical, digital health, and provider organizations should build real-world evidence programs to demonstrate symptom improvement, adherence, maternal functioning, patient-reported outcomes, safety, and health economic value. Partnerships with payers, hospitals, community health workers, lactation consultants, and maternal advocacy organizations can improve trust and reduce dropout. Companies should also invest in culturally adapted education, multilingual support, and privacy-first digital engagement to address stigma, underdiagnosis, and care discontinuity.

Research Methodology

This executive summary is based on verified secondary research and triangulated insights from public health agencies, regulatory bodies, clinical guidelines, peer-reviewed literature, and recognized healthcare organizations. Sources considered include the WHO, CDC, U.S. FDA, ACOG, NICE, national health ministries, and published studies on postpartum depression prevalence, screening, clinical burden, and treatment pathways.

The methodology emphasizes data validity over speculative market claims. Findings were assessed by comparing epidemiology, regulatory milestones, treatment pathways, reimbursement signals, digital health adoption, and regional healthcare capacity. Qualitative insights were structured to support focused executive decision-making while avoiding unsupported market sizing, market share, or forecast-based claims.

Conclusion

Postpartum depression treatment is entering a more specialized, evidence-driven phase shaped by condition-specific medicines, broader screening, telehealth, AI-enabled workflow support, and integrated maternal mental healthcare. The opportunity for improved outcomes is significant because postpartum depression is common, underdiagnosed, and associated with measurable health and social consequences when left untreated.

Future leadership will depend on improving access, affordability, clinical validation, safety monitoring, and continuity of care across the postpartum year. Organizations that combine proven therapies with digital enablement, culturally competent outreach, and rigorous evidence standards will be best positioned to improve outcomes for mothers, infants, and families worldwide.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Postpartum Depression Treatment Market, by Treatment Type
7.1. Non-Pharmacological
7.1.1. Psychotherapy
7.1.1.1. Cognitive Behavioral Therapy
7.1.1.2. Interpersonal Therapy
7.1.2. Neuromodulation
7.1.3. Digital Therapeutics
7.1.3.1. Mobile App-based Therapy
7.1.3.2. Telehealth Counseling
7.2. Pharmacological
7.2.1. Antidepressants
7.2.1.1. SSRIs
7.2.1.2. SNRIs
7.2.2. Hormonal Therapy
7.2.3. Neuroactive Steroid Therapy
7.2.3.1. Brexanolone-based
7.2.3.2. Zuranolone-based
8. Postpartum Depression Treatment Market, by Patient Severity
8.1. Mild
8.2. Moderate
8.3. Severe
9. Postpartum Depression Treatment Market, by Age Group
9.1. Below 25 Years
9.2. Between 25 To 44 Years
9.3. Above 44 Years
10. Postpartum Depression Treatment Market, by End User
10.1. Hospitals
10.2. Specialty Clinics
10.3. Mental Health Centers
10.4. Homecare Settings
11. Postpartum Depression Treatment Market, by Distribution Channel
11.1. Hospital Pharmacy
11.2. Online Pharmacy
11.3. Retail Pharmacy
12. Asia-Pacific Postpartum Depression Treatment Market
13. Europe Postpartum Depression Treatment Market
14. North America Postpartum Depression Treatment Market
15. Latin America Postpartum Depression Treatment Market
16. Africa Postpartum Depression Treatment Market
17. Middle East Postpartum Depression Treatment Market
18. NATO Postpartum Depression Treatment Market
19. G7 Postpartum Depression Treatment Market
20. European Union Postpartum Depression Treatment Market
21. BRICS Postpartum Depression Treatment Market
22. ASEAN Postpartum Depression Treatment Market
23. GCC Postpartum Depression Treatment Market
24. United States Postpartum Depression Treatment Market
25. China Postpartum Depression Treatment Market
26. Germany Postpartum Depression Treatment Market
27. Japan Postpartum Depression Treatment Market
28. India Postpartum Depression Treatment Market
29. United Kingdom Postpartum Depression Treatment Market
30. France Postpartum Depression Treatment Market
31. Canada Postpartum Depression Treatment Market
32. Italy Postpartum Depression Treatment Market
33. Australia Postpartum Depression Treatment Market
34. South Korea Postpartum Depression Treatment Market
35. Brazil Postpartum Depression Treatment Market
36. Mexico Postpartum Depression Treatment Market
37. Russia Postpartum Depression Treatment Market
38. Spain Postpartum Depression Treatment Market
39. Competitive Landscape
39.1. Market Concentration Analysis, 2025
39.1.1. Concentration Ratio (CR)
39.1.2. Herfindahl Hirschman Index (HHI)
39.2. Recent Developments & Impact Analysis, 2025
39.3. Product Portfolio Analysis, 2025
39.4. Benchmarking Analysis, 2025
40. Company Profiles
40.1. AbbVie Inc
40.2. Acadia Pharmaceuticals Inc
40.3. Amneal Pharmaceuticals LLC
40.4. AstraZeneca plc
40.5. Aurobindo Pharma Ltd
40.6. Axsome Therapeutics Inc
40.7. Biogen Inc
40.8. Brii Biosciences Limited
40.9. Dr Reddys Laboratories Ltd
40.10. Eli Lilly and Company
40.11. GH Research Ireland Limited
40.12. H. Lundbeck AS
40.13. Johnson & Johnson Services, Inc.
40.14. Lupin Ltd
40.15. Marinus Pharmaceuticals Inc
40.16. Merck & Co Inc
40.17. Mitsubishi Tanabe Pharma Corporation
40.18. Novartis AG
40.19. Otsuka Pharmaceutical Co Ltd
40.20. Pfizer Inc
40.21. Sage Therapeutics Inc
40.22. Sanofi SA
40.23. Takeda Pharmaceutical Company Limited
40.24. Teva Pharmaceutical Industries Ltd
List of Figures
FIGURE 1. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025 VS 2032 (%)
FIGURE 17. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 21. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 23. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 25. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 37. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 49. CHINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 50. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. JAPAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. INDIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. FRANCE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. CANADA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. ITALY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. AUSTRALIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. SOUTH KOREA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. BRAZIL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. MEXICO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. RUSSIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. SPAIN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL NON-PHARMACOLOGICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL NON-PHARMACOLOGICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL NON-PHARMACOLOGICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL PSYCHOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL PSYCHOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL PSYCHOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL COGNITIVE BEHAVIORAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL COGNITIVE BEHAVIORAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL COGNITIVE BEHAVIORAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL INTERPERSONAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL INTERPERSONAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL INTERPERSONAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL NEUROMODULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL NEUROMODULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL DIGITAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL MOBILE APP-BASED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL MOBILE APP-BASED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL MOBILE APP-BASED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL TELEHEALTH COUNSELING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL TELEHEALTH COUNSELING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL TELEHEALTH COUNSELING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL SSRIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL SSRIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL SSRIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL SNRIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL SNRIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL SNRIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL HORMONAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL HORMONAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL HORMONAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL NEUROACTIVE STEROID THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL NEUROACTIVE STEROID THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL NEUROACTIVE STEROID THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL BREXANOLONE-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL BREXANOLONE-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL BREXANOLONE-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ZURANOLONE-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ZURANOLONE-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ZURANOLONE-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL MILD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL MILD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL MILD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL MODERATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL MODERATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL MODERATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL SEVERE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL SEVERE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL SEVERE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL BELOW 25 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL BELOW 25 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL BELOW 25 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL BETWEEN 25 TO 44 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL BETWEEN 25 TO 44 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL BETWEEN 25 TO 44 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL ABOVE 44 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ABOVE 44 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ABOVE 44 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL MENTAL HEALTH CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL MENTAL HEALTH CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL MENTAL HEALTH CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 104. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 105. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 112. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 114. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 115. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 116. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 117. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 118. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 119. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
TABLE 120. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
TABLE 121. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 122. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 123. EUROPE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 124. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 125. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 126. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 127. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 128. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 129. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 130. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 131. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
TABLE 132. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
TABLE 133. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 134. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 135. NORTH AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 136. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 137. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 138. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 139. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 140. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 141. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 142. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 143. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
TABLE 144. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
TABLE 145. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 146. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 147. LATIN AMERICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 148. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 149. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 150. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 151. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 152. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 153. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 154. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 155. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
TABLE 156. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
TABLE 157. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 158. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 159. AFRICA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 160. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 161. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 162. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 163. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 164. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 165. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 166. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 167. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
TABLE 168. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
TABLE 169. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 170. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 171. MIDDLE EAST POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 172. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 173. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 174. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 175. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 176. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 177. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 178. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 179. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
TABLE 180. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
TABLE 181. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 182. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 183. NATO POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 184. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 185. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 186. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 187. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 188. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 189. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 190. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 191. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
TABLE 192. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
TABLE 193. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 194. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 195. G7 POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 201. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 202. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 203. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
TABLE 204. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
TABLE 205. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 206. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 207. EUROPEAN UNION POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 208. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 209. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 210. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 211. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 212. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 213. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 214. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 215. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
TABLE 216. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
TABLE 217. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 218. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 219. BRICS POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 220. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 221. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 222. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 223. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 224. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 225. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 226. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 227. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
TABLE 228. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
TABLE 229. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 230. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 231. ASEAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 232. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 233. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 234. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 235. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 236. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 237. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 238. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 239. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
TABLE 240. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
TABLE 241. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 242. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 243. GCC POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 244. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 245. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 246. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 247. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 248. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 249. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 250. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 251. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
TABLE 252. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
TABLE 253. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 254. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 255. UNITED STATES POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 256. CHINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 257. CHINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 258. CHINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 259. CHINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 260. CHINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 261. CHINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 262. CHINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 263. CHINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
TABLE 264. CHINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
TABLE 265. CHINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 266. CHINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 267. CHINA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 268. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 269. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 270. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 271. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 272. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 273. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 274. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 275. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
TABLE 276. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
TABLE 277. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 278. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 279. GERMANY POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 280. JAPAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 281. JAPAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 282. JAPAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 283. JAPAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 284. JAPAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 285. JAPAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 286. JAPAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 287. JAPAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
TABLE 288. JAPAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
TABLE 289. JAPAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 290. JAPAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 291. JAPAN POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 292. INDIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 293. INDIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 294. INDIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 295. INDIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 296. INDIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 297. INDIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 298. INDIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 299. INDIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
TABLE 300. INDIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
TABLE 301. INDIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 302. INDIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 303. INDIA POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 304. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 305. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 306. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 307. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 308. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 309. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 310. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 311. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
TABLE 312. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
TABLE 313. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 314. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 315. UNITED KINGDOM POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 316. FRANCE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 317. FRANCE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 318. FRANCE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 319. FRANCE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
TABLE 320. FRANCE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
TABLE 321. FRANCE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
TABLE 322. FRANCE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 323. FRANCE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY NEUROACTIVE STEROID THERAPY, 2018-2032 (USD MILLION)
TABLE 324. FRANCE POSTPARTUM DEPRESSION TREATMENT MARKET SIZE, BY PATIENT SEVERITY, 2018-2032 (USD MILLION)
TABLE 325. FRANCE POSTPARTUM DEPRESSION TR

Companies Mentioned

The companies featured in this Postpartum Depression Treatment market report include:
  • AbbVie Inc
  • Acadia Pharmaceuticals Inc
  • Amneal Pharmaceuticals LLC
  • AstraZeneca plc
  • Aurobindo Pharma Ltd
  • Axsome Therapeutics Inc
  • Biogen Inc
  • Brii Biosciences Limited
  • Dr Reddys Laboratories Ltd
  • Eli Lilly and Company
  • GH Research Ireland Limited
  • H. Lundbeck AS
  • Johnson & Johnson Services, Inc.
  • Lupin Ltd
  • Marinus Pharmaceuticals Inc
  • Merck & Co Inc
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Otsuka Pharmaceutical Co Ltd
  • Pfizer Inc
  • Sage Therapeutics Inc
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd

Table Information

Report AttributeDetails
No. of Pages199
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.15 Billion
Forecasted Market Value ( USD ) by 2032 $ 1.8 Billion
Compound Annual Growth Rate7.6%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Postpartum Depression Drugs Market Report: Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025-2030 - Product Image

Postpartum Depression Drugs Market Report: Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025-2030

  • Report
  • 81 Pages
  • Global
From
Postpartum Depression Market Report 2026 - Product Image

Postpartum Depression Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Postpartum Depression Treatment Market Report 2026 - Product Image

Postpartum Depression Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Postpartum Depression Drugs Market - Global Strategic Business Report - Product Image

Postpartum Depression Drugs Market - Global Strategic Business Report

  • Report
  • 479 Pages
  • Global
From
Postpartum Depression Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035 - Product Image

Postpartum Depression Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035

  • Report
  • 141 Pages
  • Global
From

About the Postpartum Depression Drug Market

The Postpartum Depression Drug market is a subset of the Mental Disorders Drugs market. Postpartum depression is a type of depression that can occur in women after childbirth. It is estimated to affect up to 20% of women after giving birth. Postpartum depression drugs are used to treat the symptoms of postpartum depression, such as sadness, anxiety, and fatigue. These drugs are typically prescribed by a doctor and can include antidepressants, psychotherapy, and hormone therapy. The Postpartum Depression Drug market is a growing market, with an increasing number of women being diagnosed with postpartum depression. The market is expected to continue to grow as more women seek treatment for postpartum depression. Some companies in the Postpartum Depression Drug market include Eli Lilly, Pfizer, GlaxoSmithKline, and Johnson & Johnson. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.